Quantum-Si reports FY2022 net loss of $132.4M; begins Platinum shipments, expects Q1 2023 revenue

Quantum-Si Inc

Q4 2022 net loss $33.1M vs $29.4M in Q4 2021; FY2022 net loss $132.4M vs $95.0M in FY2021.
Cash and investments $351.3M as of Dec 31, 2022; company projects cash runway into 2026.
Launched Platinum protein sequencer in Dec 2022; began shipments early Q1 2023; expects first revenue in Q1 2023.
Non-GAAP operating expenses expected approximately flat in 2023 vs 2022; restructuring to reduce costs.
Hired Grace Johnston as Chief Commercial Officer; partnered with Aviva Systems Biology and Biovista.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Quantum-Si Inc reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $33.1 million in the fourth quarter of 2022, compared to a net loss of $29.4 million in the fourth quarter.

Period: the fourth quarter and full year ended December 31, 2022
Net income: Net loss was $33.1 million in the fourth quarter of 2022, compared to a net loss of $29.4 million in the fourth quarter
Result: reported results

Exact text from the filing

On March 6, 2023, Quantum-Si Incorporated (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2022 and providing a business update.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Quantum-Si Inc filing history →

Source: SEC EDGAR

accession 0001140361-23-010228

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.